We are pleased to announce that our manufacturing subsidiary, Syn-The-All (STA) Pharmaceuticals Co.,  has begun construction of  a new, fully integrated R&D and cGMP manufacturing site in Changzhou, about 10 miles west of Shanghai.  This new construction aims to meet the rapidly growing  demand for WuXi’s manufacturing services, which have quadrupled their revenue in the past four years.  It is expected to be operational by the end of 2015.

Upon completion, this site will triple current capacity and have more than 1,500 employees to help clients seamlessly move new chemical  entities from early stage process development through pre-clinical  and clinical deliveries to commercial production.  This project  furthers our commitment to providing partners worldwide with highly efficient and cost-effective solutions that help bring better medicines faster to patients


Related links:

See official press release Here.
WuXi Breaks Ground on New Cell Therapy Manufacturing Facility